Roger Newman Rosenberg
Physician in Dallas, TX
License number
Colorado 19886
Issued Date
Jan 13, 1976
Renew Date
May 31, 1983
Expiration Date
May 31, 1983
Type
Physician
Address
Address
4116 Nyerwood Ln, Dallas, TX 75234
Professional information
Professor Of Neurology At Ut Southwestern
Position:
Professor of Neurology at UT Southwestern
Location:
Dallas/Fort Worth Area
Industry:
Research
Work:
UT Southwestern
-
Professor of Neurology
Dr. Roger N Rosenberg, Dallas TX - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
UT Southwestern Neurology Clnc
5303 Harry Hines Blvd STE 10, Dallas 75390
(214) 645-8800 (Phone)
5959 Harry Hines Blvd, Dallas 75235
(214) 648-9574 (Phone)
5303 Harry Hines Blvd STE 10, Dallas 75390
(214) 645-8800 (Phone)
5959 Harry Hines Blvd, Dallas 75235
(214) 648-9574 (Phone)
Certifications:
Neurology, 1971
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
UT Southwestern Neurology Clnc
5303 Harry Hines Blvd STE 10, Dallas 75390
5959 Harry Hines Blvd, Dallas 75235
Ut Southwestern University Hospital
5909 Harry Hines Blvd, Dallas 75390
5303 Harry Hines Blvd STE 10, Dallas 75390
5959 Harry Hines Blvd, Dallas 75235
Ut Southwestern University Hospital
5909 Harry Hines Blvd, Dallas 75390
Education:
Medical School
Northwestern University The Feinberg School Of Medicine
Graduated: 1964
Harvard Med Serv/Beth Israel Hospital
Graduated: 1965
Presby Hospital Columbia P&S
Graduated: 1968
Northwestern University The Feinberg School Of Medicine
Graduated: 1964
Harvard Med Serv/Beth Israel Hospital
Graduated: 1965
Presby Hospital Columbia P&S
Graduated: 1968
Amyloid Β Gene Vaccines
US Patent:
7479550, Jan 20, 2009
Filed:
Jun 2, 2006
Appl. No.:
11/445936
Inventors:
Roger N. Rosenberg - Dallas TX, US
Stephen A. Johnston - Tempe AZ, US
Stephen A. Johnston - Tempe AZ, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
International Classification:
C07H 21/04, A01N 43/04, A61K 39/12, A61K 39/00
US Classification:
536 231, 514 44, 4241921, 4241861
Abstract:
The invention generally concerns compositions and methods for genetic vaccination with amyloid beta (Aβ) protein. Such vaccines may provide effective treatment for neurodegenerative disease such as Alzheimer's disease. Vaccination methods are can be used to induce a Th2 type immune response directed to Aβ. This immune response id shown to substantially reduce Aβ concentration and Aβ plaque size in an Alzheimer's model system.